Aureus Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Aureus Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,035	Closed	-$408K	–	186
2023 Q1	$408K	Sell	2,035 -528	-21%	-$111K	0.03%	131
2022 Q4	$609K	Hold	2,563	–	–	0.05%	114
2022 Q3	$513K	Hold	2,563	–	–	0.04%	118
2022 Q2	$374K	Hold	2,563	–	–	0.03%	141
2022 Q1	$419K	Buy	+2,563	New	+$390K	0.03%	160
2016 Q4	–	Sell	-136,867	Closed	-$9.28M	–	163
2016 Q3	$9.28M	Buy	136,867 +3,016	+2%	+$213K	1.86%	24
2016 Q2	$7.43M	Buy	133,851 +1,960	+1%	+$123K	1.6%	28
2016 Q1	$8.28M	Buy	131,891 +65,256	+98%	+$4.34M	1.81%	30
2015 Q4	$6.27M	Buy	+66,635	New	+$6.18M	1.41%	29
2015 Q3	–	Sell	-34,808	Closed	-$4.17M	–	157
2015 Q2	$4.17M	Sell	34,808 -160	-0.5%	-$19.1K	0.88%	41
2015 Q1	$3.65M	Buy	34,968 +170	+0.5%	+$17.2K	0.84%	43
2014 Q4	$3.38M	Hold	34,798	–	–	0.82%	44
2014 Q3	$2.72M	Sell	34,798 -49,983	-59%	-$3.22M	0.68%	44
2014 Q2	$5.36M	Buy	+84,781	New	+$5.04M	1.34%	39

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Aureus Asset Management's ALNY Position: Q2 2023 in Review

Aureus Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 2,035 shares — an estimated $408K sold.

Aureus Asset Management first reported a position in ALNY in Q2 2014 and held it in 14 quarters. The position peaked at $9.28M in Q3 2016. 477 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

Aureus Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Aureus Asset Management sold 2,035 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $408K.
Aureus Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 14 quarters.
Aureus Asset Management's Alnylam Pharmaceuticals position peaked at $9.28M in Q3 2016.
477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Aureus Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.